AAM is the nation’s leading trade association for manufacturers and distributors of generic and biosimilar prescription medicines, manufacturers of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. AAM is a strong voice in advocating the interests of its member companies before federal and state lawmakers, regulatory policymakers and international agencies.
A career at AAM means the opportunity to work on behalf of the generic and biosimilar industry at the center of the most important healthcare policy issues facing our nation. The working environment is high-energy, fast-paced; and the culture is entrepreneurial. AAM provides a competitive salary and benefits package including medical, dental, vision, life and disability insurance, 401k match, on-site fitness center, vacation, sick pay and tuition reimbursement.
Director/Senior Director, Strategic Alliances
Please email jobs@accessiblemeds.org to submit a resume and cover letter.
Team members at the Association for Accessible Medicines (AAM) share a commitment to ensuring America’s patients have access to the medicines they need to thrive. With access to safe and effective generic and biosimilar medicines, the health outcomes and lifestyles of patients improve.
AAM team members are able to spark new initiatives when the need arises. One example is the Women in Health Policy (WiHP) network which emerged out of the need for women to amplify their professional advancement and share their cross-sector health care policy experience and expertise.
This nonpartisan community prioritizes inclusion and diverse perspectives. This network grew to over 500 members in just the first year!
The AAM team also participates annually to contribute to homeless shelters and other charities that support health and well-being in the Washington D.C. area.’
Generic and biosimilar medicines make it easier and more affordable for patients to live healthier lives.
Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.
For the latest updates, follow us on social media.
